In the clinical NAFLD study, in patients with uncontrolled T2DM, GLP-1 agonist, liraglutide leads to weight loss and liver fat reduction [88]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.